| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza Vaccines | 20 | 2025 | 481 | 3.560 |
Why?
|
| Immunogenicity, Vaccine | 19 | 2026 | 115 | 3.320 |
Why?
|
| Influenza, Human | 19 | 2025 | 674 | 2.980 |
Why?
|
| Antibodies, Viral | 35 | 2026 | 1133 | 2.700 |
Why?
|
| Antibodies, Neutralizing | 24 | 2026 | 496 | 2.270 |
Why?
|
| Influenza A Virus, H7N9 Subtype | 7 | 2025 | 27 | 2.140 |
Why?
|
| Immunization, Secondary | 12 | 2025 | 114 | 1.970 |
Why?
|
| Vaccines | 7 | 2025 | 384 | 1.900 |
Why?
|
| Influenza A Virus, H7N7 Subtype | 2 | 2020 | 11 | 1.260 |
Why?
|
| HIV Infections | 10 | 2025 | 1954 | 1.230 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 5 | 2021 | 59 | 1.150 |
Why?
|
| Adjuvants, Immunologic | 12 | 2025 | 380 | 1.140 |
Why?
|
| Vaccines, Inactivated | 11 | 2025 | 146 | 1.100 |
Why?
|
| Respiratory Tract Infections | 3 | 2026 | 279 | 1.050 |
Why?
|
| Mycobacterium tuberculosis | 6 | 2013 | 409 | 0.930 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2025 | 13 | 0.910 |
Why?
|
| Histoplasmosis | 1 | 2025 | 55 | 0.890 |
Why?
|
| Hemagglutination Inhibition Tests | 14 | 2025 | 110 | 0.890 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2025 | 71 | 0.880 |
Why?
|
| Zika Virus Infection | 5 | 2024 | 176 | 0.830 |
Why?
|
| Vaccination | 17 | 2026 | 1003 | 0.820 |
Why?
|
| Tuberculosis | 5 | 2014 | 539 | 0.820 |
Why?
|
| Adult | 59 | 2026 | 30628 | 0.810 |
Why?
|
| Humans | 106 | 2026 | 127593 | 0.800 |
Why?
|
| Polysorbates | 7 | 2025 | 25 | 0.760 |
Why?
|
| Squalene | 7 | 2025 | 25 | 0.760 |
Why?
|
| Bacteremia | 2 | 2019 | 420 | 0.760 |
Why?
|
| Pandemics | 5 | 2025 | 1141 | 0.740 |
Why?
|
| Zika Virus | 5 | 2024 | 152 | 0.700 |
Why?
|
| Microcephaly | 2 | 2024 | 344 | 0.700 |
Why?
|
| Middle Aged | 45 | 2026 | 27899 | 0.660 |
Why?
|
| Influenza in Birds | 1 | 2020 | 26 | 0.640 |
Why?
|
| Clostridium septicum | 1 | 2019 | 2 | 0.620 |
Why?
|
| Liver Abscess, Pyogenic | 1 | 2019 | 3 | 0.620 |
Why?
|
| Male | 60 | 2026 | 62943 | 0.610 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 196 | 0.600 |
Why?
|
| Viral Vaccines | 4 | 2026 | 314 | 0.590 |
Why?
|
| Antitubercular Agents | 4 | 2013 | 263 | 0.590 |
Why?
|
| Population Surveillance | 5 | 2013 | 395 | 0.590 |
Why?
|
| Viral Load | 3 | 2024 | 398 | 0.570 |
Why?
|
| Encephalitis | 1 | 2019 | 117 | 0.570 |
Why?
|
| Young Adult | 26 | 2026 | 9704 | 0.570 |
Why?
|
| Hemagglutinins | 2 | 2021 | 25 | 0.550 |
Why?
|
| Acanthamoeba | 1 | 2017 | 9 | 0.540 |
Why?
|
| Amebiasis | 1 | 2017 | 11 | 0.540 |
Why?
|
| Female | 59 | 2026 | 68816 | 0.530 |
Why?
|
| Immunization Schedule | 7 | 2025 | 104 | 0.520 |
Why?
|
| Antiprotozoal Agents | 1 | 2017 | 41 | 0.520 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 439 | 0.510 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 257 | 0.490 |
Why?
|
| Anthrax Vaccines | 5 | 2016 | 26 | 0.480 |
Why?
|
| Clostridium Infections | 1 | 2019 | 242 | 0.480 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2011 | 382 | 0.480 |
Why?
|
| Smallpox Vaccine | 3 | 2025 | 38 | 0.480 |
Why?
|
| Spike Glycoprotein, Coronavirus | 5 | 2024 | 204 | 0.470 |
Why?
|
| RNA, Viral | 3 | 2024 | 511 | 0.460 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 308 | 0.460 |
Why?
|
| Double-Blind Method | 16 | 2026 | 1602 | 0.450 |
Why?
|
| Francisella tularensis | 2 | 2017 | 16 | 0.440 |
Why?
|
| Seizures | 1 | 2019 | 844 | 0.440 |
Why?
|
| Bacterial Vaccines | 2 | 2017 | 104 | 0.430 |
Why?
|
| Guatemala | 6 | 2024 | 64 | 0.430 |
Why?
|
| Adolescent | 31 | 2026 | 20176 | 0.420 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2013 | 185 | 0.410 |
Why?
|
| Disease Outbreaks | 2 | 2008 | 308 | 0.410 |
Why?
|
| Clinical Trials as Topic | 6 | 2025 | 1110 | 0.390 |
Why?
|
| Adenosine Monophosphate | 2 | 2024 | 47 | 0.380 |
Why?
|
| Aged | 22 | 2026 | 20524 | 0.370 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2005 | 230 | 0.370 |
Why?
|
| Antigens, Viral | 2 | 2024 | 392 | 0.370 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 972 | 0.370 |
Why?
|
| Alanine | 2 | 2024 | 162 | 0.370 |
Why?
|
| Injections, Intradermal | 5 | 2025 | 29 | 0.360 |
Why?
|
| Dengue | 2 | 2024 | 121 | 0.360 |
Why?
|
| Urban Population | 1 | 2013 | 276 | 0.350 |
Why?
|
| Antibodies, Bacterial | 7 | 2017 | 421 | 0.350 |
Why?
|
| Aza Compounds | 1 | 2011 | 12 | 0.350 |
Why?
|
| Immunoglobulin G | 10 | 2025 | 794 | 0.340 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2026 | 73 | 0.330 |
Why?
|
| Malaria Vaccines | 1 | 2010 | 25 | 0.330 |
Why?
|
| Quinolines | 1 | 2011 | 112 | 0.330 |
Why?
|
| Antigens, Protozoan | 1 | 2010 | 80 | 0.320 |
Why?
|
| Malaria, Falciparum | 1 | 2010 | 68 | 0.320 |
Why?
|
| RNA, Messenger | 4 | 2023 | 2539 | 0.310 |
Why?
|
| Case-Control Studies | 6 | 2025 | 3336 | 0.310 |
Why?
|
| Orthomyxoviridae | 2 | 2011 | 51 | 0.300 |
Why?
|
| Protozoan Proteins | 1 | 2010 | 133 | 0.300 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 1350 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2024 | 1206 | 0.290 |
Why?
|
| Anthrax | 3 | 2014 | 30 | 0.290 |
Why?
|
| Treatment Outcome | 11 | 2025 | 12600 | 0.280 |
Why?
|
| Child Development | 2 | 2021 | 266 | 0.280 |
Why?
|
| Brain | 1 | 2019 | 3034 | 0.270 |
Why?
|
| Tuberculosis, Central Nervous System | 1 | 2007 | 11 | 0.270 |
Why?
|
| Antiviral Agents | 2 | 2024 | 778 | 0.260 |
Why?
|
| Injections, Intramuscular | 9 | 2025 | 182 | 0.260 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2024 | 825 | 0.250 |
Why?
|
| Vaccines, Synthetic | 6 | 2022 | 316 | 0.250 |
Why?
|
| Organophosphonates | 1 | 2006 | 21 | 0.240 |
Why?
|
| Injections, Subcutaneous | 6 | 2025 | 129 | 0.240 |
Why?
|
| United States | 10 | 2025 | 11427 | 0.240 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2006 | 33 | 0.240 |
Why?
|
| Chikungunya virus | 1 | 2026 | 27 | 0.240 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2025 | 9 | 0.240 |
Why?
|
| Chikungunya Fever | 1 | 2026 | 32 | 0.240 |
Why?
|
| Polymorphism, Genetic | 3 | 2004 | 788 | 0.230 |
Why?
|
| Texas | 8 | 2013 | 3566 | 0.230 |
Why?
|
| Immunity, Mucosal | 1 | 2025 | 83 | 0.230 |
Why?
|
| Placebos | 5 | 2016 | 226 | 0.230 |
Why?
|
| Adenine | 1 | 2006 | 116 | 0.230 |
Why?
|
| Histoplasma | 1 | 2025 | 37 | 0.230 |
Why?
|
| Administration, Mucosal | 1 | 2025 | 1 | 0.230 |
Why?
|
| Infant | 9 | 2024 | 12842 | 0.220 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2017 | 221 | 0.220 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2005 | 81 | 0.220 |
Why?
|
| Patient Acuity | 2 | 2021 | 64 | 0.220 |
Why?
|
| Creatinine | 1 | 2006 | 385 | 0.210 |
Why?
|
| Mannose-Binding Lectin | 1 | 2004 | 4 | 0.210 |
Why?
|
| Single-Blind Method | 2 | 2021 | 237 | 0.210 |
Why?
|
| Research Design | 2 | 2026 | 694 | 0.210 |
Why?
|
| Azetidines | 2 | 2022 | 64 | 0.210 |
Why?
|
| Purines | 2 | 2022 | 110 | 0.210 |
Why?
|
| Area Under Curve | 1 | 2024 | 303 | 0.210 |
Why?
|
| Dengue Virus | 2 | 2024 | 131 | 0.210 |
Why?
|
| Nasopharynx | 1 | 2024 | 86 | 0.210 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2017 | 58 | 0.200 |
Why?
|
| Schistosomiasis mansoni | 1 | 2023 | 24 | 0.200 |
Why?
|
| Incidence | 4 | 2021 | 3265 | 0.190 |
Why?
|
| Water Microbiology | 1 | 2002 | 26 | 0.190 |
Why?
|
| Water Supply | 1 | 2002 | 25 | 0.190 |
Why?
|
| Aedes | 1 | 2023 | 100 | 0.190 |
Why?
|
| Vancomycin | 1 | 2024 | 221 | 0.190 |
Why?
|
| Antifungal Agents | 1 | 2025 | 296 | 0.190 |
Why?
|
| Mycobacterium | 1 | 2002 | 30 | 0.190 |
Why?
|
| Azithromycin | 1 | 2022 | 43 | 0.190 |
Why?
|
| Vomiting | 1 | 2023 | 100 | 0.190 |
Why?
|
| Mycobacterium Infections | 1 | 2002 | 32 | 0.190 |
Why?
|
| Cough | 1 | 2023 | 97 | 0.190 |
Why?
|
| Vaccinia virus | 2 | 2025 | 50 | 0.190 |
Why?
|
| Sulfonamides | 2 | 2022 | 280 | 0.190 |
Why?
|
| Follow-Up Studies | 5 | 2026 | 5170 | 0.180 |
Why?
|
| Growth Disorders | 1 | 2023 | 183 | 0.180 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2021 | 13 | 0.180 |
Why?
|
| Healthy Volunteers | 4 | 2026 | 149 | 0.180 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 61 | 0.180 |
Why?
|
| Pyrazoles | 2 | 2022 | 330 | 0.180 |
Why?
|
| Vaccines, Attenuated | 3 | 2017 | 173 | 0.170 |
Why?
|
| Diarrhea | 1 | 2023 | 305 | 0.170 |
Why?
|
| Aged, 80 and over | 5 | 2023 | 6718 | 0.170 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2021 | 45 | 0.170 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2024 | 472 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 785 | 0.170 |
Why?
|
| DNA, Bacterial | 3 | 2011 | 482 | 0.170 |
Why?
|
| Emigration and Immigration | 1 | 2000 | 81 | 0.160 |
Why?
|
| Critical Illness | 1 | 2024 | 603 | 0.160 |
Why?
|
| Prospective Studies | 6 | 2024 | 6266 | 0.160 |
Why?
|
| Occupational Health | 1 | 2020 | 46 | 0.160 |
Why?
|
| Mycobacterium avium Complex | 2 | 2021 | 20 | 0.160 |
Why?
|
| Birds | 1 | 2020 | 86 | 0.160 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2021 | 167 | 0.160 |
Why?
|
| Motor Skills | 1 | 2020 | 75 | 0.160 |
Why?
|
| Lipid A | 1 | 2019 | 23 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2025 | 535 | 0.150 |
Why?
|
| Language Tests | 1 | 2019 | 24 | 0.150 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2024 | 522 | 0.150 |
Why?
|
| Cytokines | 3 | 2020 | 1321 | 0.150 |
Why?
|
| Schistosomiasis | 1 | 2019 | 52 | 0.150 |
Why?
|
| Cross Infection | 1 | 2002 | 334 | 0.150 |
Why?
|
| Glucosides | 1 | 2019 | 53 | 0.150 |
Why?
|
| Antibodies, Helminth | 1 | 2019 | 131 | 0.150 |
Why?
|
| Body Fluids | 1 | 2019 | 46 | 0.150 |
Why?
|
| Acute Kidney Injury | 1 | 2006 | 664 | 0.150 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 92 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2019 | 1231 | 0.140 |
Why?
|
| Workflow | 1 | 2019 | 134 | 0.140 |
Why?
|
| Language Development Disorders | 1 | 2019 | 177 | 0.140 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 484 | 0.130 |
Why?
|
| Tularemia | 1 | 2017 | 13 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 989 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 2517 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2021 | 396 | 0.130 |
Why?
|
| Influenza B virus | 2 | 2023 | 98 | 0.130 |
Why?
|
| Child, Preschool | 8 | 2024 | 14512 | 0.130 |
Why?
|
| Immunoglobulin A | 2 | 2025 | 205 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 285 | 0.130 |
Why?
|
| Learning | 1 | 2020 | 357 | 0.120 |
Why?
|
| Child | 7 | 2024 | 25352 | 0.120 |
Why?
|
| Drug Carriers | 1 | 2017 | 116 | 0.120 |
Why?
|
| Pneumococcal Vaccines | 1 | 2017 | 174 | 0.120 |
Why?
|
| Caregivers | 1 | 2021 | 563 | 0.120 |
Why?
|
| Coccidioidomycosis | 1 | 2015 | 9 | 0.120 |
Why?
|
| Cohort Studies | 5 | 2022 | 4991 | 0.120 |
Why?
|
| Pneumococcal Infections | 1 | 2017 | 278 | 0.120 |
Why?
|
| Cholecystitis | 1 | 2015 | 20 | 0.120 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2015 | 24 | 0.110 |
Why?
|
| Health Personnel | 1 | 2020 | 535 | 0.110 |
Why?
|
| Streptococcus pneumoniae | 1 | 2017 | 380 | 0.110 |
Why?
|
| Biomarkers | 1 | 2024 | 3254 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 363 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 376 | 0.110 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2014 | 11 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 342 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2015 | 132 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2004 | 3273 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 261 | 0.100 |
Why?
|
| Animals | 7 | 2023 | 33175 | 0.100 |
Why?
|
| Molecular Epidemiology | 2 | 2005 | 145 | 0.100 |
Why?
|
| End Stage Liver Disease | 1 | 2015 | 184 | 0.100 |
Why?
|
| Risk Factors | 4 | 2013 | 10645 | 0.090 |
Why?
|
| Psychometrics | 3 | 2021 | 655 | 0.090 |
Why?
|
| Bacillus anthracis | 2 | 2009 | 39 | 0.090 |
Why?
|
| China | 2 | 2024 | 277 | 0.090 |
Why?
|
| Prevalence | 2 | 2011 | 2626 | 0.090 |
Why?
|
| Erythema Infectiosum | 1 | 2011 | 5 | 0.090 |
Why?
|
| Mortality | 1 | 2013 | 254 | 0.090 |
Why?
|
| Schistosoma mansoni | 2 | 2023 | 24 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 337 | 0.090 |
Why?
|
| Parvovirus B19, Human | 1 | 2011 | 26 | 0.090 |
Why?
|
| Coinfection | 1 | 2013 | 185 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 227 | 0.090 |
Why?
|
| Molecular Typing | 1 | 2011 | 32 | 0.090 |
Why?
|
| Ofloxacin | 1 | 2011 | 30 | 0.090 |
Why?
|
| Aluminum Compounds | 1 | 2010 | 16 | 0.080 |
Why?
|
| alpha-Tocopherol | 2 | 2024 | 36 | 0.080 |
Why?
|
| Fluoroquinolones | 1 | 2011 | 93 | 0.080 |
Why?
|
| Human Experimentation | 1 | 2010 | 32 | 0.080 |
Why?
|
| Exanthema | 1 | 2011 | 73 | 0.080 |
Why?
|
| Rural Population | 2 | 2024 | 247 | 0.080 |
Why?
|
| Antibody Formation | 2 | 2025 | 267 | 0.080 |
Why?
|
| Phosphates | 1 | 2010 | 108 | 0.080 |
Why?
|
| Antibodies, Protozoan | 1 | 2010 | 98 | 0.080 |
Why?
|
| Plasmodium falciparum | 1 | 2010 | 94 | 0.080 |
Why?
|
| Pregnancy | 4 | 2024 | 7425 | 0.080 |
Why?
|
| Drug Combinations | 2 | 2024 | 271 | 0.080 |
Why?
|
| Influenza A virus | 1 | 2010 | 148 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2025 | 17111 | 0.080 |
Why?
|
| Vaccines, DNA | 1 | 2009 | 45 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 2895 | 0.080 |
Why?
|
| Logistic Models | 2 | 2005 | 1791 | 0.070 |
Why?
|
| Immunoglobulin M | 1 | 2009 | 211 | 0.070 |
Why?
|
| Drug Administration Schedule | 3 | 2021 | 736 | 0.070 |
Why?
|
| HIV-1 | 1 | 2012 | 469 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 3723 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 2082 | 0.070 |
Why?
|
| Europe | 1 | 2008 | 363 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 291 | 0.070 |
Why?
|
| Interferon-gamma | 1 | 2009 | 528 | 0.060 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 1 | 2006 | 10 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3589 | 0.060 |
Why?
|
| Measles virus | 1 | 2026 | 16 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 1296 | 0.060 |
Why?
|
| Tenofovir | 1 | 2006 | 23 | 0.060 |
Why?
|
| Research | 1 | 2008 | 257 | 0.060 |
Why?
|
| Neutralization Tests | 2 | 2017 | 225 | 0.060 |
Why?
|
| Neuropsychological Tests | 2 | 2020 | 962 | 0.060 |
Why?
|
| Bacterial Proteins | 1 | 2011 | 914 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 1712 | 0.060 |
Why?
|
| Immunity, Humoral | 1 | 2025 | 73 | 0.060 |
Why?
|
| Cities | 1 | 2004 | 49 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2004 | 75 | 0.050 |
Why?
|
| Urban Health | 1 | 2004 | 84 | 0.050 |
Why?
|
| Genes, MHC Class I | 1 | 2023 | 12 | 0.050 |
Why?
|
| Carrier State | 1 | 2004 | 80 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 2 | 2000 | 195 | 0.050 |
Why?
|
| Benzoin | 1 | 2023 | 6 | 0.050 |
Why?
|
| Probability | 1 | 2004 | 309 | 0.050 |
Why?
|
| Vaccines, Combined | 1 | 2023 | 39 | 0.050 |
Why?
|
| Aluminum Hydroxide | 1 | 2023 | 40 | 0.050 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2023 | 132 | 0.050 |
Why?
|
| Brazil | 1 | 2023 | 138 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 239 | 0.050 |
Why?
|
| Reference Values | 1 | 2004 | 686 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2024 | 304 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2004 | 278 | 0.050 |
Why?
|
| Protozoan Vaccines | 1 | 2023 | 99 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 1388 | 0.050 |
Why?
|
| Bacterial Toxins | 2 | 2016 | 171 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 161 | 0.050 |
Why?
|
| Cation Transport Proteins | 1 | 2002 | 99 | 0.050 |
Why?
|
| Time Factors | 1 | 2012 | 6173 | 0.040 |
Why?
|
| Seasons | 1 | 2023 | 318 | 0.040 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2021 | 25 | 0.040 |
Why?
|
| Antigens, Bacterial | 2 | 2016 | 313 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2022 | 256 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2004 | 882 | 0.040 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2020 | 27 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1485 | 0.040 |
Why?
|
| Ethambutol | 1 | 2000 | 6 | 0.040 |
Why?
|
| Translations | 1 | 2020 | 17 | 0.040 |
Why?
|
| Recurrence | 1 | 2004 | 1429 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2024 | 8391 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 92 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 327 | 0.040 |
Why?
|
| HIV Seropositivity | 1 | 2000 | 124 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 52 | 0.040 |
Why?
|
| Age Distribution | 1 | 2000 | 423 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2000 | 410 | 0.040 |
Why?
|
| Translating | 1 | 2019 | 28 | 0.040 |
Why?
|
| Rural Health | 1 | 2019 | 40 | 0.040 |
Why?
|
| Child Language | 1 | 2019 | 28 | 0.040 |
Why?
|
| Culturally Competent Care | 1 | 2019 | 50 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 541 | 0.040 |
Why?
|
| Semen | 1 | 2019 | 83 | 0.040 |
Why?
|
| Antigens, Helminth | 1 | 2019 | 187 | 0.040 |
Why?
|
| Saliva | 1 | 2019 | 130 | 0.030 |
Why?
|
| Mothers | 1 | 2021 | 363 | 0.030 |
Why?
|
| Agglutination Tests | 1 | 2017 | 8 | 0.030 |
Why?
|
| Seroconversion | 1 | 2017 | 15 | 0.030 |
Why?
|
| Serogroup | 1 | 2017 | 65 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 489 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1154 | 0.030 |
Why?
|
| Equivalence Trials as Topic | 1 | 2017 | 21 | 0.030 |
Why?
|
| Viral Plaque Assay | 1 | 2017 | 42 | 0.030 |
Why?
|
| Vagina | 1 | 2019 | 203 | 0.030 |
Why?
|
| Baculoviridae | 1 | 2017 | 41 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2006 | 3711 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2017 | 105 | 0.030 |
Why?
|
| Emulsions | 1 | 2017 | 69 | 0.030 |
Why?
|
| Milk, Human | 1 | 2019 | 308 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1602 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1050 | 0.030 |
Why?
|
| Hemagglutination, Viral | 1 | 2015 | 9 | 0.030 |
Why?
|
| Immunization | 1 | 2017 | 304 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2015 | 53 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2004 | 3598 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2015 | 218 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 1712 | 0.020 |
Why?
|
| Emigrants and Immigrants | 1 | 2015 | 165 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 259 | 0.020 |
Why?
|
| Hospitalization | 1 | 2020 | 1878 | 0.020 |
Why?
|
| Pharynx | 1 | 2011 | 64 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 3938 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 525 | 0.020 |
Why?
|
| Capsid Proteins | 1 | 2011 | 143 | 0.020 |
Why?
|
| Nose | 1 | 2011 | 103 | 0.020 |
Why?
|
| New York | 1 | 2009 | 69 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2009 | 81 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 149 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 2814 | 0.020 |
Why?
|
| Rabbits | 1 | 2009 | 628 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 17648 | 0.020 |
Why?
|
| Safety | 1 | 2006 | 213 | 0.010 |
Why?
|
| Dinucleotide Repeats | 1 | 2002 | 6 | 0.010 |
Why?
|
| Carbohydrate Dehydrogenases | 1 | 2000 | 3 | 0.010 |
Why?
|
| Pentosyltransferases | 1 | 2000 | 14 | 0.010 |
Why?
|
| Operon | 1 | 2000 | 48 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2002 | 394 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2000 | 786 | 0.010 |
Why?
|